Saturday 17 October 2026 Export CYVNY’s income statement to Excel — free account

Ceryvyn Therapeutics Ltd. - Unsponsored ADR

Ceryvyn Therapeutics Ltd. - Unsponsored ADR’s revenue for fiscal 2025 (year ended June 2025) was $25,000.00, down 80.0% from fiscal 2024.

0.02 0.00 0.00%

Follow CYVNY

Alert me

Market cap: $524.8M
P/E: 0.0×
Fwd P/E: −4.9×
Dividend yield: —
F-score: 3/9
Altman Z: −30.38
Beneish M: −3.64
Dividend safety: n/a

Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 524.83

Revenue 0.23

Net Income 0.00

Free Cash Flow (461.65)

Net Debt (48.44)

Current Ratio 0.22

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (4.94)

P/S ratio 2.37

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 79.65%

Next Y EPS Growth 92.28%

Next Y revenue growth 3,065.47%

Next 5Y EPS Growth 68.97%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 12.63%

10-year low 10-year high

EV/Sales against its own 10 years 65.47%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2022	2023	2024	2025
Cash	45	89	172	48
Receivables	7	7	12	8
Inventory	—	—	—	—
Other	9	3	4	1
	60	98	188	57

	2022	2023	2024	2025
Payables	11	18	38	10
ST’ Debt	—	—	—	—
Other	1	1	26	248
	12	19	64	258

Compound Annual Growth %

	10y	5y	3y
Sales	—	(15.81%)	(34.92%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	0
’24	—	—	—	—	0
’23	—	—	—	—	0
’22	—	—	—	—	0
’21	—	—	—	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(159)
’24	—	—	—	—	(161)
’23	—	—	—	—	(121)
’22	—	—	—	—	(71)
’21	—	—	—	—	(46)
’20	—	—	—	3	(6)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	(159)	—	(73)	(159)
’24	—	(161)	—	(69)	(161)
’23	—	(121)	—	(69)	(121)
’22	—	(71)	—	(29)	(71)
’21	—	(45)	—	(17)	(45)
’20	—	(6)	—	3	(5)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(1.06)
’24	—	—	—	—	(2.76)
’23	—	—	—	—	(2.58)
’22	—	—	—	—	(2.11)
’21	—	—	—	—	(1.13)
’20	—	—	—	(0.02)	(0.34)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	1.40	3.60	2.27	3.84	10.22	6.07	4.51	1.60	1.79	0.01	Analyst estimates 2026–2028 Powerpack
	High	4.00	12.80	12.80	20.82	21.36	16.23	8.50	6.09	5.45	6.30
People
People	Employees	—	—	—	—	8	9	18	24	34	4
	Revenue/emp, $m	—	—	—	—	0.01	0.01	0.01	0.00	0.00	0.01
Income, $m
Income, $m	Revenue	—	—	—	—	0	0	0	0	0	0
	Gross margin, %	0.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(6)	(7)	(21)	(25)	(17)	(50)	(99)	(148)	(230)	(170)
	EBT margin, %	0.00	0.00	0.00	0.00	(28,480.54)	(73,299.27)	(109,279.71)	(136,944.10)	(183,723.20)	(678,952.00)
	Net income	(5)	0	(13)	(15)	—	—	—	—	—	—
	Depreciation	0	0	0	0	—	—	—	—	—	—
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(0.03)	(0.03)	(0.06)	(0.06)	(0.33)	(1.13)	(2.11)	(2.58)	(2.76)	(1.06)
	Cash flow	0.00	(0.20)	(0.51)	(0.52)	(0.17)	(1.14)	(1.62)	(2.18)	(2.02)	(1.04)
	Capex	0.00	0.00	0.00	0.00	0.01	0.02	0.00	0.00	0.00	0.00
	Free cash flow	0.00	(0.20)	(0.51)	(0.52)	(0.16)	(1.12)	(1.62)	(2.18)	(2.02)	(1.04)
	Book value	0.00	1.80	0.97	0.67	1.37	3.38	1.09	(0.11)	(0.95)	(1.31)
	Shares, m	—	23	29	33	33	40	44	55	80	153
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	0.00	0.00	0.00	332.48	225.61	404.91
	P/B	—	—	—	—	11.53	1.61	3.59	0.00	0.00	0.00
	EV/Sales	—	—	—	—	0.00	0.00	0.00	317.97	347.87	1,161.82
	EV/FCF	—	—	—	—	(17.20)	(1.48)	(0.79)	(0.25)	(0.19)	(0.58)
Cash, $m
Cash, $m	Operating cash flow	(3)	(5)	(15)	(17)	(6)	(46)	(71)	(121)	(161)	(159)
	Capex	0	0	0	0	0	1	0	0	0	0
	Free cash flow	(3)	(5)	(15)	(17)	(5)	(45)	(71)	(121)	(161)	(159)
Balance, $m
Balance, $m	Working capital	11	41	28	21	44	135	48	80	124	(201)
	Total debt	—	—	—	—	0	0	—	86	201	—
	Net debt	(11)	(40)	(24)	(15)	(43)	(118)	(45)	(3)	28	(48)
	Shareholders’ equity	11	42	28	22	45	135	48	(6)	(76)	(201)
Returns, %
Returns, %	ROA	(17.23)	(75.13)	(53.49)	(48.37)	(29.36)	(48.28)	(93.54)	(179.62)	(153.25)	(132.57)
	ROIC	0.00	0.00	0.00	0.00	(517.79)	(144.96)	(1,803.34)	0.00	0.00	0.00
	ROE	(18.24)	(17.96)	(35.67)	(58.45)	(33.54)	(50.42)	(101.29)	(676.68)	539.40	117.59

Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
VALN Valneva SE Sponsored ADR	$560.4M	59.7×	19.4×	−17.29% (below 0%: shrinking)	n/m	−56.05% (below 0%: shrinking)	15.29%	(76.67%)	Compare
STTK Shattuck Labs, Inc.	$555.0M	— (loss-making)	— (loss-making)	−10.31% (below 0%: shrinking)	n/m	+1.01% (above 0%: growing)	100.00%	0.00%	Compare
VECT VectivBio Holding AG	$545.5M	— (loss-making)	— (loss-making)	—	n/m	—	91.93%	0.00%	Compare
PBYI Puma Biotechnology, Inc.	$543.0M	18.2×	24.2×	+7.75% (above 0%: growing)	+33.33% (above 0%: growing)	−88.45% (below 0%: shrinking)	77.92%	13.42%	Compare
DRUG Bright Minds Biosciences Inc.	$534.7M	— (loss-making)	—	—	n/m	−124.63% (below 0%: shrinking)	0.00%	0.00%	Compare
FTH Faeth Therapeutics, Inc.	$532.3M	— (loss-making)	—	—	n/m	−174.24% (below 0%: shrinking)	0.00%	0.00%	Compare
CTMX CytomX Therapeutics, Inc.	$525.1M	— (loss-making)	— (loss-making)	−92.40% (below 0%: shrinking)	n/m	−14.50% (below 0%: shrinking)	100.00%	(1,677.08%)	Compare
CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR	$524.8M	— (loss-making)	— (loss-making)	−7.53% (below 0%: shrinking)	n/m	−31.52% (below 0%: shrinking)	0.00%	0.00%
ACRS Aclaris Therapeutics, Inc.	$513.7M	— (loss-making)	— (loss-making)	−8.33% (below 0%: shrinking)	n/m	−98.77% (below 0%: shrinking)	10.80%	(1,487.91%)	Compare
Median of peers	$538.9M	—	—	−10.31%	—	−88.45%	46.61%	0.00%

All 614 Biotechnology stocks →

Ceryvyn Therapeutics Ltd. - Unsponsored ADR (CYVNY) key facts

Concern: Ceryvyn Therapeutics Ltd. - Unsponsored ADR’s revenue for fiscal 2025 (year ended June 2025) was $25,000.00, down 80.0% from fiscal 2024.
Ceryvyn Therapeutics Ltd. - Unsponsored ADR (CYVNY) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 15, 2026, CYVNY traded at $0.02, a market capitalization of $524.8 million.
Return on equity was 117.6% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −30.38 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.